Latest Safety News

Prescient Therapeutics has initiated its first US clinical site for the PTX-100 Phase 2a trial targeting Cutaneous T-Cell Lymphoma, marking a key milestone in expanding patient recruitment beyond Australia.

Phoslock Environmental Technologies reported a $474,000 cashflow deficit in Q2 2025, with sales impacted by deferred European projects and ongoing US tariff uncertainties. Factory refurbishment delays push production restart to early 2026.

dorsaVi confirms its licensed 40nm Resistive RAM technology delivers high-speed, low-power performance ideal for next-generation embedded and edge AI platforms. This breakthrough supports advanced wearable sensors and neuromorphic computing applications.

Li-S Energy has appointed Paladin Defense Services as its U.S. representative to accelerate engagement with the Department of Defense and defence contractors, aiming to commercialise its advanced battery technology in a critical market.

Evolution Mining has delivered record cash flow for FY25, meeting its original production and cost guidance amid high metal prices, while setting a confident outlook for FY26 with continued strong cash generation expected.

Terrain Minerals has wrapped up an expanded nearly 5,000-meter gold drilling campaign at its Lightning and Monza prospects within the Smokebush Project, with assay results expected in August 2025.

MC Mining’s subsidiary, Uitkomst Colliery, has launched a strategic Turnaround Plan aimed at operational restructuring and cost reduction, positioning the mine for growth amid a challenging coal market.

Rio Tinto has appointed Simon Trott as its new Chief Executive, effective August 25, 2025, marking a leadership transition focused on operational excellence and shareholder value.

Syntara Limited has initiated dosing in its Phase 1c SATELLITE trial for a novel topical treatment targeting keloid scars, marking a significant step in addressing a $3.5 billion global market. The study, led by Professor Fiona Wood, will evaluate safety and early efficacy over three months.

Prescient Therapeutics has extended its Share Purchase Plan closing date to 22 July 2025, aiming to raise up to A$7 million to advance its targeted cancer therapy PTX-100 through Phase 2 clinical trials.

X2M Connect Limited has launched a $4.9 million capital raising through a Placement and Entitlement Offer to reduce debt and accelerate expansion in IoT, AI, and renewable energy markets.

St Barbara Limited reported a robust Q4 June 2025 with gold sales surging 34% and full-year production meeting guidance, supported by a strong cash position and improved safety metrics.